LYCOS RETRIEVER 
Organon: Akzo Nobel
built 650 days ago
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas ... include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.
Source:
Organon, the human healthcare business of Akzo Nobel, and Shanghai Genomics Inc, the China-based affiliate of GNI and one of China’s leading biotech companies, today announced an agreement to collaborate on a new research project. The collaboration, which will involve biological development work aimed at progressing Organon’s program for the identification of more selective steroid hormone receptor modulators, will initially last for a period of two years.
Source:
Organon, the healthcare business of Akzo Nobel, is to go into a collaborative research agreement with UK firm Sareum Holdings. The aim of the agreement is to develop new therapies for autoimmune diseases such as rheumatoid arthritis.
Source:
Organon is the largest of the three pharmaceutical business units of Akzo Nobel, a leading global company in health care products, coatings and chemicals. Headquartered in The Netherlands, Akzo Nobel currently employs 67,900 people in 80 countries.
Source:
Organon is one jewel in the West of Scotland's life science crown that cannot afford to be ignored. A subsidiary company of global biotech powerhouse Akzo Nobel, the organisation has chosen to base its entire UK research division in Newhouse, Lanarkshire.
Source:
At the same time, the offer quashes Akzo's plan to spin off Organon as a separate company through a partial stock offering on the Amsterdam Stock Exchange. The Schering-Plough offer exceeds both Akzo's $9 billion estimate of proceeds from a stock market launch and analysts' recent estimates that a buyer might pay about $10 billion for the business (C&EN, March 5, page 37).
Source:
MORE ABOUT
Akzo Nobel